Business Context and Reporting Period
This Form 8-K Current Report was filed by Global Medical REIT Inc. (not Chiron Real Estate Inc.) on August 25, 2017. The registrant is a Maryland corporation and an emerging growth company. The report details the entry into a material definitive agreement regarding a new equity offering program.
Key Financial Metrics
This filing does not contain financial performance data such as revenue, profit, cash flow, margins, debt, or liquidity metrics. The document focuses exclusively on the authorization of a new capital raising mechanism.
Material Changes and Agreements
On August 25, 2017, the Company entered into Sales Agreements with Cantor Fitzgerald & Co. and FBR Capital Markets & Co. to establish an "at-the-market" (ATM) equity offering program. Key terms include:
- Aggregate Offering Amount: Up to $50,000,000 of common stock.
- Compensation: Agents are entitled to up to 3.0% of the gross proceeds from shares sold.
- Flexibility: The Company has no obligation to sell any shares and may suspend the offering at any time.
- Registration: Shares will be issued pursuant to a Registration Statement on Form S-3 (File No. 333-217360).
Outlook, Risks, and Management Commentary
Management has established a flexible mechanism to raise capital through the open market. The filing notes that the Company will reimburse certain expenses incurred by the agents. No specific guidance on future sales volume or timing was provided in this report. The filing includes standard legal disclaimers stating that the report does not constitute an offer to sell securities in jurisdictions where such an offer would be unlawful.
Investor Verification Checklist
- Verify the exact name of the registrant is Global Medical REIT Inc., not Chiron Real Estate Inc.
- Confirm the total authorized amount of $50,000,000 under the new Sales Agreements.
- Review the 3.0% commission fee payable to Cantor Fitzgerald & Co. and FBR Capital Markets & Co.
- Check the status of the underlying Form S-3 Registration Statement (File No. 333-217360).
- Note that the Company retains the right to suspend the offering at any time without obligation to sell.